Development Of Allogeneic CAR T Cells As A Potential Therapy For Acute Myeloid Leukemia

Allogeneic CAR T-cell therapy holds significant promise as an accessible “off-the-shelf” treatment for Acute Myeloid Leukemia (AML), a hematological malignancy with limited therapeutic options. However, efficient and scalable development of these therapies presents considerable challenges. This application note details how MaxCyte’s ExPERT™ platform empowers the streamlined development of allogeneic CAR T-cells targeting AML.

Utilizing MaxCyte’s innovative Flow Electroporation™ technology, the platform facilitates one-step double gene knockout and efficient CAR transgene delivery, achieving superior cell engineering efficiency and enhanced scalability essential for clinical and commercial manufacturing. By overcoming traditional bottlenecks in cell engineering and manufacturing, the ExPERT platform accelerates the progress of allogeneic CAR T-cell therapies towards clinical viability for AML patients.

Access the complete application note to explore how MaxCyte’s ExPERT platform can help unlock the full potential of allogeneic CAR T-cell development for AML treatment.